TMO International Revenues Show Bifurcation, No Rush to Buy

What happened

Thermo Fisher’s international sales, which account for over half of total revenue, are split between resilient pharma/biotech services demand and cyclical academic/government instrument headwinds, a pattern confirmed by the latest data. Recent overseas trends reveal that while bioprocessing and clinical services sustain mid-single-digit organic growth in developed markets, China’s economic slowdown and European academic caution are dragging on reported numbers. Currency translation and a strong dollar are further masking underlying improvements, making headline international growth look weaker than true operating performance. The company’s 10-Q filings detail restructuring efforts and tariff/FX margin pressure in Analytical Instruments, underscoring that near-term international profitability will be a tug-of-war between volume growth and cost absorption. Until there’s clearer evidence of a broad-based international recovery—likely tied to Clario’s integration and a stabilization in China—the risk/reward remains balanced at current levels.

Implication

Investors should monitor international organic revenue growth, particularly in services, as a proxy for thesis health. Sustained mid-single-digit growth in pharma services across Europe and Asia would support a more constructive view, while deepening declines in academic/government or China could compress the multiple further. The upcoming Q1 FY2026 results will provide the first real test of whether international demand is stabilizing or softening. Moreover, progress on the Clario acquisition—which could accelerate international clinical workflow sales—is a gating item; a delayed close or synergy downgrade would warrant a more conservative stance. Should international organic growth dip below 3% or Clario face unexpected hurdles, a pullback toward the $470 attractive entry would offer a better margin of safety.

Thesis delta

The new international revenue analysis confirms the existing thesis dynamics—pharma/biotech demand remains the bright spot while academic/government and China continue to weigh. The data do not shift the needle enough to change the WAIT rating. The next 90 days, with Q1 FY2026 results and Clario regulatory updates, will be the true catalysts for a reassessment.